5:19 PM
 | 
Aug 30, 2012
 |  BC Extra  |  Company News

Sarepta jumps on media optimism for DMD therapy

Sarepta Therapeutics Inc. (NASDAQ:SRPT) jumped $1.80 (14%) to $14.40 on Thursday after a Missouri television station aired an anecdotal report about improvements in a Duchenne muscular dystrophy (DMD) patient receiving the company's eteplirsen in a Phase IIb trial. The...

Read the full 180 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >